I
mmunosuppressive therapies have meaningful effects on the treatment of multiple sclerosis (MS), a classical inflammatory autoimmune disease of the central nervous system. 1 In mice with experimental autoimmune encephalomyelitis (EAE), a murine model of human MS, we showed that an adoptive transfer of GM-CSF and Interleukin-15 Fusion Transgene (GIFT15)-derived regulatory B cells (GIFT15 B regs ) sustained a durable remission of the disease. 2, 3 These regulatory B cells require the expression of MHC class II and IL-10 for suppressive activity. 2 In EAE mice, the adoptive transfer of regulatory B cells (B regs ) induces the formation of conventional FoxP3 + regulatory T cells, as well as type 1 regulatory T cells, the CD49b + CD223 + subset, reversing neuroinflammation and inducing the remission of symptoms. 3 A chronic neuroinflammatory process similar to MS, including microglial activation and the infiltration of bloodborne macrophages is observed in amyotrophic lateral sclerosis (ALS) animal models and patients. In human ALS spinal cords, there is a dense infiltration of macrophages, with a corresponding expression of pro-inflammatory cytokines. 4 Here, we tested if GIFT15 B regs exhibited neuroprotective effects in SOD1-G93A mice, a murine model of ALS, as observed in the EAE model.
Effect of the adoptive transfer of GIFT15 B regs into a SOD1-G93A mouse model ALS is a clinically heterogeneous motor neuron disease, resulting in paralysis and death. Animal models of ALS uncover multiple potential mechanisms of motor neuron injury and drivers of disease progression, and one hypothesized mechanism of disease progression in ALS is neuroinflammation. 5 Data from ALS models show that there is a wellharmonized dialogue between motor neurons, microglia and adaptive immune cells and that motor neuron death is accompanied by a neuroinflammatory response that is characterized by microglial activation and an increased frequency of myeloid-derived macrophages and T cells infiltrating the affected regions. 6 In these models, microglial activation increases over time and is associated with the release of proinflammatory cytokines and the increased recruitment of blood-derived macrophages. Multiple immunosuppressive regimens have been tested in ALS patients, including corticosteroids, plasmapheresis, intravenous immunoglobulin, cyclophosphamide, and cyclosporine. 7 Unfortunately, none of these treatments ameliorated disease progression.
We showed that in mice with EAE, the adoptive transfer of GIFT15 B regs induced the formation of regulatory T cells, conventional FoxP3 + , T regs , and Tr1 cells and resulted in the complete remission of EAE symptoms. These regulatory T-cells reversed neuroinflammation and neurological dysfunction by decreasing the frequency of effector T cells in lymphoid organs (spleen and MLN), as well as in the CNS of the EAE mice. Since IL-10 producing T cells are a promising cellular therapy for ALS patients, 8 we tested the effect of the GIFT15 B regs adoptive therapy in SOD1-G93A mice.
SOD1-G93A mice were injected intravenously with either GIFT15 B regs or control splenocytes (5 million cells) once a week for 3 weeks every month. Survival was not significantly prolonged in the GIFT15 B regs -treated mice and only a modest improvement in the rotarod a b e s Figure 1 GIFT15 B regs adoptive transfer effect in SOD1-G93A and non-carrier littermate mice. Bar graph of the T reg or Tr1 frequencies in the MLN, spleen and CNS (a) and the infiltrating macrophages and microglia after the GIFT15 B regs adoptive transfer (b). The bar graphs are the mean ± s.d. values of two independent experiments (biological replicates), with n = 3 per group. The black bars are the mice treated with splenocytes, and the gray bars are mice treated with GIFT15 B regs . The p values were calculated using a two-tailed Student's t test: *Po0.05; **Po0.01; ***Po0.001.
performance was observable in the surviving mice treated with GIFT15 B regs .
In SOD1-G93A mice, GIFT15 B regs homed to the spleen and mesenteric lymph nodes (MLN), increasing the frequency of regulatory T cells, namely, CD4 + CD25 + FoxP3 + cells and Tr1, CD4 + CD49b + CD223 + /LAG-3 + cells. Within the first month of the post-adoptive transfer in SOD1-G93A mice and noncarrier littermates (3 months of age), a higher frequency of regulatory T cells was observed in the MLN (P = 0.02 for non-carrier littermate and P = 0.002 for SOD1-G93A mice, respectively). In the MLN of the SOD1-G93A mice, the frequency of T regs in the GIFT15 B regstreated group increased more than 2-fold compared to the mice treated with unstimulated splenocytes. Tr1 regulatory T cells increased more than 3-fold in the GIFT15 B regs -treated group within the first month of the post-adoptive transfer (P = 0.0009). After the first month, we observed no differences in the T cell populations in the MLN between the two groups of SOD1-G93A mice (Figure 1a) . Similarly, a higher frequency of regulatory T cells was observed in the spleens of the SOD1-G93A animals treated with GIFT15 B regs compared to the controls (Figure 1a , P = 0.02). However, the relative increase in the regulatory T cells, both T regs and Tr1, in the spleens of the animals treated with GIFT15 B regs , persisted for up to 5 months in the SOD1-G93A mice and up to 6 months in the non-carrier littermates (Figure 1a) . The effect of the GIFT15 B regs on the frequency of the regulatory T cells in the CNS was delayed compared to the spleen and MLN in the SOD1-G93A mice. Increases in the T regs and Tr1 were noticeable in the CNS only at 5 months (Figure 1a , P = 0.02 and P = 0.005 for T regs and Tr1, respectively), whereas in the non-carrier littermates, they were noticeable only at 3 months of age ( Figure 1a , P = 0.008 and P = 0.009 for T regs and Tr1, respectively). In a recent study, Beers et al. 8 showed that in the G93A ALS mouse model, the passive transfer of regulatory T cells prolonged survival and slowed the disease. Moreover, these investigators also reported that, in ALS patients, there was an inverse correlation between the level of FoxP3 + T cells in the peripheral blood and the rate of the progression of the disease. Also of interest is a recent small trial of T cell vaccination in ALS, which reported a slowing of disease in seven treated patients. 9 A current clinical trial is testing the use of autologous regulatory T cells as a novel therapy for ALS. 10 Infiltrating macrophages in the CNS of SOD1-G93A mice An increased frequency of regulatory T cells was evident at five months in the CNS of the SOD1-G93A GIFT15 B regs -treated mice (Figure 1b) . To better understand if the treatment with GIFT15 B regs had any effect in the CNS infiltrating cell composition, the spinal cords and brains were collected and analyzed for leukocyte content in cohorts of treated and untreated SOD1-G93A mice every month post adoptive transfer.
Samples isolated with Percoll gradients separated into two primary populations, including CD45 int and CD45 high . Differences in the surface expression of CD45 antigen relate to the distinction between microglia (CD11b + CD45 int ) and bloodderived myeloid cells (CD11b + CD45 high ). The phenotype of resting microglia differs from other populations of tissue macrophages. Since they are more similar to immature myeloid cells, microglia express only low levels of CD45 antigen.
In non-transgenic littermates, between 1 and 2% of the population in each cell preparation was classified as CD45 high myeloid macrophages (Figure 1b) . In the SOD1-G93A mice, the frequency of blood-derived macrophages in the CNS was between 2 and 3% (Figure 1b) . The adoptive transfer of GIFT15 B regs in the SOD1-G93A mice decreased the frequency of infiltrating macrophages to a level comparable to that observed in the non-carrier littermates for up to 5 months (Figure 1b , P = 0.03 at 3 months, P = 0.02 at 4 months and P = 0.04 at 5 months, respectively). There is evidence that disease progression and motor neuron death in ALS is associated with a substantial immune response by microglia, astrocytes, infiltrating T cells and blood-derived macrophages. 4 We showed that a GIFT15 B regs adoptive transfer is associated with a trend towards improved neuromuscular function in the surviving SOD-G93A mice but did not prolong the overall survival. Interestingly, the major effect observed in the CNS of mice treated with GIFT15 B regs was a decreased frequency of myeloid macrophages compared to splenocytes in the treated SOD1-G93A mice. The frequency of macrophages in the GIFT15 B regs -treated group was comparable to the amount observed in the noncarrier littermates. We showed here that the GIFT15 B regs -treated mice had fewer CNS-infiltrating macrophages compared to the mice treated with splenocytes. Furthermore, the same activated macrophages are found in the CNS of other neurological conditions, such as Alzheimer's disease. Our results showed that the adoptive transfer of the GIFT15 B regs normalized the content of myeloid macrophages in the CNS to levels comparable to that observed in the normal mice. Ongoing studies are investigating whether the depletion of macrophages in the CNS is potentially beneficial for reducing brain inflammation in ALS and other neurodegenerative diseases.
Distinct from traditional immune suppressive strategies that typically attempt to deplete or counteract the number and function of pathogenic lymphomyeloid cells, the use of GIFT15 B regs normalizes the CNS immune homeostasis by augmenting the endogenous suppressor cell number and functionality. As a whole, our data suggest that autologous GIFT15 B regs deploy an innate functionality, leading to the peripheral expansion of neurotropic IL-10 + T-cells whose effect is immunoregulatory and, possibly, regenerative. These observations inform a translational cell therapy strategy where autologous GIFT15 B regs in human subjects with ALS may alter clinical outcomes by reshaping the CNS immune ecosystem.
